Yarrowia lipolytica lipase ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
298	Hereditary pancreatitis	2

298. Hereditary pancreatitis

---

Clinical trials : 98 /  Drugs : 180 - (DrugBank : 57) / Drug target genes : 53 - Drug target pathways : 142

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03481803 (ClinicalTrials.gov)	January 27, 2017	6/3/2018	A Phase IIa Study With Escalating Dose of MS1819-SD	A Multicentre Open-label Phase IIa Study With Escalating Dose of MS1819- SD, to Investigate the Efficacy and Safety of a Yarrowia Lipolytica Lipase Preparation for the Compensation of Exocrine Pancreatic Insufficiency Caused by Chronic Pancreatitis and/or Distal Pancreatectomy	Chronic Pancreatitis;Distal Pancreatectomy	Drug: MS1819-SD	AzurRx SAS	NULL	Completed	18 Years	N/A	All	11	Phase 2	Australia;France;New Zealand
2	EUCTR2010-018900-10-FR (EUCTR)	11/05/2010	19/03/2010	Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis	Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis	Exocrine pancreatic insufficiency resulting from chronic pancreatitis MedDRA version: 12.1;Level: LLT;Classification code 10033628;Term: Pancreatic insufficiency	Product Name: MS1819 Product Code: MS1819 INN or Proposed INN: Yarrowia lipolytica lipase	Laboratoires Mayoly Spindler	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	12		France